CytomX Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Good morning, everyone. This session is for CytomX. My name is Ash Verma, and I'm part of the [Smith Capitec and Spec Pharma] team here at Bank of America. And CytomX is a clinical stage biotech company with a focus on cancer immunotherapy. And with me today is Sean McCarthy, Chairman, President and CEO of CytomX. Over to you, Sean.
Great. Thank you very much, Ash, and good morning, everyone. Thanks for joining us today. It's a pleasure to be here to provide an update on our recent progress and future directions at CytomX. So moving to Slide 2, our forward-looking statements. I want to remind you that over the next 30 minutes or so, I will be making certain forward-looking statements, and I refer you to our safe harbor statement. Now this has been a very busy year for us at CytomX. We've had many achievements so far this year. And abstracts were, of course, released yesterday for several presentations at ASCO.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
